Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gates Commits $89m To Novavax After Maternal RSV Vaccine Success

This article was originally published in Scrip

Executive Summary

Now that Novavax Inc.'s respiratory syncytial virus (RSV) vaccine has succeeded in a Phase II clinical trial in pregnant women, the Bill & Melinda Gates Foundation has committed up to $89m to help the company fund a massive Phase III trial that will include sites in developing countries.

You may also be interested in...



FDA Panel To Weigh Animal, Adult Human Data For Initiation Of RSV Vaccine Trials In Infants

Sponsors have been increasingly developing vaccine candidates for the respiratory syncytial virus with an unmet need existing for infants; the advisory committee will evaluate FDA's proposed approach for developing candidates in the target population.

Novavax’s Phase III RSV Vaccine Failure Wipes Out Nearly $2bn In Value

Novavax shocked investors with negative results for its RSV vaccine in a Phase III clinical trial immunizing older adults, but promised more data – and ideas for a potential second Phase III trial – in October.

Case Studies: How Three Public Companies Financed R&D In A Tough Market

The market for public offerings by biopharma companies is tough, but Corbus Pharmaceuticals, Loxo Oncology and Novavax used three different strategies to raise cash from new and existing shareholders.

Topics

Related Companies

UsernamePublicRestriction

Register

SC029894

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel